




A




B




C




D




E




F




G



H





Supplemental Figure S4: (A) Oil Red O staining (magnification 10x, scale bar: 200 μ m). (B) TG content in the liver of *ob/ob* mice treated 5 days or 15 days with either SCR-GeRPs and NFkB-GeRPs (n= 11-13) and (C-D) mRNA levels of lipogenic genes in liver (n=5). (E) Serum FFA levels. (F) Representative western blot of total and activated (pSer473) Akt in liver. (G) mRNA levels of inflammatory genes in the liver of *ob/ob* mice treated 15 days with SCR-GeRPs and NFkB-GeRPs (n= 11-13). (H) Representative western blot and densitometry using antibodies against p473Akt, total Akt and actin using epididymal adipose tissue lysates (n=4-5). (I) mRNA levels of gluconeogenic genes in isolated hepatocytes of *ob/ob* mice treated 5 days with SCR-GeRPs or NFkB-GeRPs (n= 11-13). (J) Fasting serum insulin. (K) Expression of inflammation genes in the liver of mice fed a chow or HFD for 24 weeks (n=5). (L) Body weight of 24 week-HFD after a 15-day treatment with SCR- or NFkB-GeRPs (n=5). (M) Liver section of 24 week-HFD-fed mice treated with SCR- or NFkB-GeRPs stained with Oil Red O. Results are presented as mean of F.C. normalized to SCR-GeRPs treated mice \pm SEM. *p < 0.05; **p < 0.01. The statistical significance was analyzed by t-test or ANOVA followed by Tukey post-test.